ArticleProtein & cell2026
NSUN2‑mediated epitranscriptomic and ubiquitin modulation of Nipah virus matrix protein reveals a dual-targeting antiviral strategy.
Article in Protein & cell, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nipah virus matrix protein promotes NF-κB activation by targeting multiple signaling modulators.Journal of virology · 2026Article
- NSUN2 Promotes Cancer Immune Evasion via Its Moonlighting Function Acting on Metabolic Reprogramming.Cancer communications (London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Nipah virus (NiV) poses a significant public health threat due to its high mortality rate and the absence of approved treatments. Nonetheless, the host-virus interactions underlying its pathogenesis remain poorly understood. Here, we identified the 5-methylcytosine (m5C) methyltransferase NSUN2 as a critical host factor hijacked by NiV to facilitate replication via dual mechanisms. The viral matrix (M) protein stabilizes NSUN2 by inhibiting its proteasomal degradation. In turn, NSUN2 catalyzes m5C deposition on NiV RNAs, enhancing M RNA stability and protein expression. Simultaneously, NSUN2's noncatalytic domain engages GNB2 as an adaptor to facilitate the recruitment of the E3 ubiquitin ligase TRIM28 to M, promoting M ubiquitination and consequent nuclear export for virion assembly. Targeting both pathways using the proteasome inhibitor carfilzomib and the m5C inhibitor MY-1B suppressed NiV replication in vitro and in hamsters. Our findings uncover a dual epigenetic-posttranslational regulatory axis exploited by NiV and present a promising combinatorial therapeutic approach.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.